OverviewSuggest Edit

HTG Molecular Diagnostics is a leading provider of molecular-based technology solutions for gene expression profiling, miRNA, siRNA and mRNA measurement for translational medicine and diagnostic applications. HTG’s product offerings have since expanded to include its HTG EdgeSeq product lines, which automate sample and targeted library preparation for next-generation sequencing. The Company's qNPA molecular technology platform is well-suited for reliably detecting small, yet important, changes in gene expression levels in a variety of sample types. 

TypePublic
Founded1997
HQTucson, US
Websitehtgmolecular.com
Employee Ratings2.5

Latest Updates

Employees (est.) (Dec 2018)107(+14%)
Job Openings6
Revenue (FY, 2019)$19.2 M(-10%)
Share Price (Sept 2020)$0.4 (+4%)
Cybersecurity ratingBMore

Key People/Management at HTG Molecular Diagnostics

Timothy TJ B. Johnson

Timothy TJ B. Johnson

CEO
John L. Lubniewski

John L. Lubniewski

President, Chief Operating Officer
Shaun D. McMeans

Shaun D. McMeans

Senior Vice President of Finance, Administration and Chief Financial Officer
Patrick Pat C. Roche

Patrick Pat C. Roche

Senior Vice President, Scientific and Medical Affairs
Sam M. Rua

Sam M. Rua

Senior Vice President of Regulatory Affairs and Quality Systems
Show more

HTG Molecular Diagnostics Office Locations

HTG Molecular Diagnostics has an office in Tucson
Tucson, US (HQ)
3430 E Global Loop
Show all (1)

HTG Molecular Diagnostics Financials and Metrics

HTG Molecular Diagnostics Revenue

Embed Graph
View revenue for all periods
HTG Molecular Diagnostics's revenue was reported to be $19.20 m in FY, 2019
USD

Revenue (Q2, 2020)

2.0m

Gross profit (Q2, 2020)

988.7k

Gross profit margin (Q2, 2020), %

50.4%

Net income (Q2, 2020)

(5.7m)

EBIT (Q2, 2020)

(5.0m)

Market capitalization (18-Sept-2020)

25.1m

Closing stock price (18-Sept-2020)

0.4

Cash (30-Jun-2020)

21.0m

EV

17.0m
HTG Molecular Diagnostics's current market capitalization is $25.1 m.
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

4.0m5.1m14.8m21.5m19.2m

Revenue growth, %

27%

Cost of goods sold

3.3m4.1m5.0m5.1m8.9m

Gross profit

706.1k996.8k9.8m16.4m10.3m
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

1.0m790.6k1.0m865.2k1.9m913.9k1.4m1.8m3.7m4.2m4.9m4.7m3.2m5.8m5.4m2.2m2.0m

Cost of goods sold

894.6k834.9k809.0k843.5k933.0k1.1m1.3m1.2m1.1m1.1m1.5m1.2m2.0m2.5m2.9m1.0m974.6k

Gross profit

129.7k(44.4k)201.9k21.8k962.8k(211.1k)75.9k523.9k2.6m3.0m3.5m3.5m1.2m3.3m2.5m1.2m988.7k

Gross profit Margin, %

13%(6%)20%3%51%(23%)6%30%71%73%70%74%36%57%46%54%50%
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

3.3m7.5m10.0m8.4m7.6m

Accounts Receivable

716.2k1.4m6.4m5.0m3.2m

Prepaid Expenses

443.1k568.2k633.5k

Inventories

1.2m1.3m1.3m
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(21.4m)(26.0m)(19.0m)(16.5m)(19.3m)

Depreciation and Amortization

662.6k1.5m1.2m1.5m1.3m

Inventories

(746.2k)(33.2k)77.2k(171.9k)(116.8k)

Accounts Payable

(312.3k)10.1k1.2m(150.2k)(156.0k)
USDQ1, 2015

Financial Leverage

-0.1 x
Show all financial metrics

HTG Molecular Diagnostics Cybersecurity Score

Cybersecurity ratingPremium dataset

B

87/100

SecurityScorecard logo

HTG Molecular Diagnostics Online and Social Media Presence

Embed Graph

HTG Molecular Diagnostics News and Updates

HTG Molecular Diagnostics Reports Full Year 2019 Results

Increased product and product-related services revenue over prior year, benefitting from expanded menu of profiling assays and increased number of customers adopting technology

HTG Molecular Diagnostics Receives European Patent Grant Notification for Methods for Subtyping Diffuse Large B-cell Lymphoma

TUCSON, Ariz., Jan. 28, 2020 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced it has received notification of validation of European patent number EP 3356554 for its methods for subtypin…

HTG Molecular Diagnostics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

TUCSON, Ariz., May 24, 2019 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a diagnostic company whose mission is to advance precision medicine, today announced that on May 22, 2019 the Compensation Committee of its Board of Directors granted inducement stock options to p…

HTG Molecular Diagnostics Reports Full Year 2018 Results

Revenue increased 46% in 2018 compared to the prior year reflecting continued success growing the company’s profiling business with Pharma company customers Revenue increased 46% in 2018 compared to the prior year reflecting continued success growing the company’s profiling business with Pharma comp…

HTG Molecular Diagnostics Fulfills First Orders for its Next-Generation Sequencing-Based HTG EdgeSeq Precision Immuno-Oncology Panel

TUCSON, Ariz., Aug. 15, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a provider of instruments, reagents, and services for molecular profiling applications, today announced it launched its HTG EdgeSeq Precision Immuno-Oncology Panel and has delivered its first ord…

HTG Molecular Diagnostics and Oncologie, Inc. Complete Master Agreement to Partner on Biomarker Development for Immuno-oncology Drug Development

TUCSON, Ariz., Aug. 03, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a provider of instruments, reagents, and services for molecular profiling applications and Oncologie, Inc. an innovative biotechnology company with operations in Boston and Shanghai, today announ…
Show more

HTG Molecular Diagnostics Frequently Asked Questions

  • When was HTG Molecular Diagnostics founded?

    HTG Molecular Diagnostics was founded in 1997.

  • Who are HTG Molecular Diagnostics key executives?

    HTG Molecular Diagnostics's key executives are Timothy TJ B. Johnson, John L. Lubniewski and Shaun D. McMeans.

  • How many employees does HTG Molecular Diagnostics have?

    HTG Molecular Diagnostics has 107 employees.

  • What is HTG Molecular Diagnostics revenue?

    Latest HTG Molecular Diagnostics annual revenue is $19.2 m.

  • What is HTG Molecular Diagnostics revenue per employee?

    Latest HTG Molecular Diagnostics revenue per employee is $179.5 k.

  • Who are HTG Molecular Diagnostics competitors?

    Competitors of HTG Molecular Diagnostics include Complement Genomics, DNA Genotek and BiogeniQ.

  • Where is HTG Molecular Diagnostics headquarters?

    HTG Molecular Diagnostics headquarters is located at 3430 E Global Loop, Tucson.

  • Where are HTG Molecular Diagnostics offices?

    HTG Molecular Diagnostics has an office in Tucson.

  • How many offices does HTG Molecular Diagnostics have?

    HTG Molecular Diagnostics has 1 office.